Perampanel in the additional therapy of focal and primary generalized tonic-clonic seizures in children 4–12 years old: clinical data, experience of use and practical recommendations
https://doi.org/10.17749/2077-8333/epi.par.con.2021.087
Abstract
On March 18, 2021, an online council of experts in the field of epilepsy treatment was held, dedicated to the use of perampanel in the additional therapy of focal seizures (FS) and primary generalized tonic-clonic seizures (PGTCS) in children 4–12 years old. During the event, the features of the use of perampanel in this group of patients were discussed, considering the specifics of everyday clinical practice, current possibilities of PGTCS and FS therapy in children, its goals, as well as unsolved problems in the treatment of pediatric patients with PGTCS and FS. Particular attention was paid to the role of perampanel in the treatment of PGTCS and FS in children and its effectiveness in specific types of focal seizures.
Keywords
epilepsy,
children,
therapy features,
primary generalized tonic-clonic seizures,
focal seizures,
perampanel,
clinical practice,
quality of life
Supporting agencies: This article was published with the financial support of Eisai Co., Ltd. The authors are fully responsible for the content of the article and editorial decisions.
About the Authors
K. Yu. Mukhin
St. Luke Institute of Pediatric Neurology and Epilepsy
Russian Federation
Russian Federation
Konstantin Yu. Mukhin – Dr. Med. Sc., Professor, Head of Clinic
9 Academician Anokhin Str., Moscow 119571
E. D. Belousova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Elena D. Belousova – Dr. Med. Sc., Professor, Head of the Department of Psychoneurology and Epileptology, Research Clinical Institute of Pediatrics
1 Ostrovityanov Str., Moscow 117997
S. G. Burd
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Sergey G. Burd – Dr. Med. Sc., Professor, Chair of Neurology, Neurosurgery and Medical Genetics
1 Ostrovityanov Str., Moscow 117997
M. V. Barkhatov
Federal Siberian Scientific and Clinical Center, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Mikhail V. Barkhatov – MD, PhD, Director, Center for Epileptology and Pediatric Neurology
26 Kolomenskaya Str., Krasnoyarsk 660037
N. A. Ermolenko
Voronezh Regional Clinical Hospital No. 1
Russian Federation
Russian Federation
Natalia A. Ermolenko – Dr. Med. Sc., Head of the Neurological Departmen
151 Moskovskiy Prospect, Voronezh 394068
S. K. Zyryanov
Peoples’ Friendship University of Russia; City Clinical Hospital No. 24
Russian Federation
Russian Federation
Sergey K. Zyryanov – Dr. Med. Sc., Professor, Head of Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia; Deputy Chief Physician for Therapy, City Clinical Hospital No. 24
8 corp. 2 Miklukho-Maklay Str., Moscow 117198
10 Pistsovaya Str., Moscow 127015
E. I. Karpovich
Nizhny Novgorod Semashko Regional Clinical Hospital
Russian Federation
Russian Federation
Ekaterina I. Karpovich – Dr. Med. Sc., Head of Neurophysiology Department
190 Rodionov Str., Nizhny Novgorod 603126
E. A. Morozova
Kazan State Medical Academy – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Elena A. Morozova – Dr. Med. Sc., Professor, Head of Department of Pediatric Neurology
11 Mushtari Str., Kazan 420012
G. V. Odintsova
Almazov National Medical Research Center
Russian Federation
Russian Federation
Galina V. Odintsova – MD, PhD, Head of Research Laboratory of Epileptology
2 Akkuratov Str., Saint Petersburg 197341
References
1. Instructions for the medical use of Faikompa (perampanel) drug with changes from 07.12.2020 (RU LP002200 from 23.08.2013) (in Russ.).
2. Fogarasi A., Flamini R., Milh M., et al. Open label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to < 12 years) with inadequately controlled focal seizures or generalized tonic clonic seizures. Epilepsia. 2020; 61 (1): 125–37. https://doi.org/10.1111/epi.16413.
3. Verrotti A., Mazzocchetti C. Epilepsy: beyond seizures the importance of comorbidities in epilepsy. Nat Rev Neurol. 2016; 12: 559–60. https://doi.org/10.1038/nrneurol.2016.135.
4. Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. 2nd ed. Мoscow: BINOM; 2019: 643 pp. (in Russ.).
5. Belousova Е.D. The effect of antiepileptic drugs on cognitive functions: perampanel in focus. Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions. 2016; 8 (3): 6–10 (in Russ.). https://doi.org/10.17749/2077-8333.2016.8.3.006-010.
6. Bourgeois B.F. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carbamazepine or phenobarbital. Clin Neuropharmacol. 1988; 11 (4): 348–59. https://doi.org/10.1097/00002826-198808000-00003.
7. Verrotti A., Tambucci R., Di Francesco L., et al. The role of polytherapy in the management of epilepsy: suggestions for rational antiepileptic drug selection. Expert Review Neurother. 2020; 20 (2): 167–73. https://doi.org/10.1080/14737175.2020.1707668.
8. de Biase S., Gigli G. L., Nilo A., et al. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. Expert Opin Drug Metab Toxicol. 2019; 15 (2): 93–102. https://doi.org/10.1080/17425255.2019.1560420.
9. Pellock J.M., Arzimanoglou A., D'Cruz O.N., et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥ 2 years of age with focal seizures: the case for disease similarity. Epilepsia. 2017; 58 (10): 1686–96. https://doi.org/10.1111/epi.13859.
10. Thijs R.D., Surges R., O'Brien, T.J., Sander J.W. Epilepsy in adults. Lancet. 2019; 393 (10172): 689–701. https://doi.org/10.1016/S0140-6736(18)32596-0.
11. Camfield P., Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17 (2): 117–23. https://doi.org/10.1684/epd.2015.0736.
12. Arzimanoglou A., Kalilani L., Anamoo M.A., et al. Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy – a systematic review of the literature using lacosamide as an example. Eur J Paediatr Neurol. 2019; 23 (4): 589–603. https://doi.org/10.1016/j.ejpn.2019.05.002.
13. Nordli D.R., Bagiella E., Arzimanoglou A., et al. Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures. Neurology. 2020; 94 (17): e1845–52. https://doi.org/10.1212/WNL.0000000000009325.
14. Renfroe J.B., Mintz M., Davis R., et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to < 12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and efficacy. J Child Neurol. 2019; 34 (5): 284–94. https://doi.org/10.1177/0883073819827407.
Review
For citations:
Mukhin K.Yu., Belousova E.D., Burd S.G., Barkhatov M.V., Ermolenko N.A., Zyryanov S.K., Karpovich E.I., Morozova E.A., Odintsova G.V. Perampanel in the additional therapy of focal and primary generalized tonic-clonic seizures in children 4–12 years old: clinical data, experience of use and practical recommendations. Epilepsy and paroxysmal conditions. 2021;13(2):180-187. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2021.087
Views:
683
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
